1. ACADIA Pharmaceuticals Inc. – Product Pipeline Review – Q2 2011
ACADIA Pharmaceuticals Inc. – Product Pipeline Review – Q2 2011
Summary
Global Market Direct’s pharmaceuticals report, “ACADIA Pharmaceuticals Inc. -
Product Pipeline Review - Q2 2011” provides data on the ACADIA Pharmaceuticals
Inc.’s research and development focus. The report includes information on current
developmental pipeline, complete with latest updates, and features on discontinued
and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s
proprietary databases, ACADIA Pharmaceuticals Inc.’s corporate website, SEC
filings, investor presentations and featured press releases, both from ACADIA
Pharmaceuticals Inc. and industry-specific third party sources, put together by
Global Markets Direct’s team.
Scope
- ACADIA Pharmaceuticals Inc. - Brief ACADIA Pharmaceuticals Inc. overview
including business description, key information and facts, and its locations and
subsidiaries.
- Review of current pipeline of ACADIA Pharmaceuticals Inc. human therapeutic
division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development,
including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of ACADIA
Pharmaceuticals Inc. with complete description of the product’s developmental
history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the ACADIA Pharmaceuticals Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Browse All Pharmaceuticals Market Research Reports
Reasons to buy
- Evaluate ACADIA Pharmaceuticals Inc.’s strategic position with total access to
detailed information on its product pipeline.
- Assess the growth potential of ACADIA Pharmaceuticals Inc. in its therapy areas
of focus.
- Identify new drug targets and therapeutic classes in the ACADIA Pharmaceuticals
Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in
those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill

2. portfolio gaps.
- Exploit collaboration and partnership opportunities with ACADIA Pharmaceuticals
Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of ACADIA Pharmaceuticals Inc.
and identify potential opportunities in those areas.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
ACADIA Pharmaceuticals Inc. Snapshot 5
ACADIA Pharmaceuticals Inc. Overview 5
Key Information 5
Key Facts 5
ACADIA Pharmaceuticals Inc. – Research and Development Overview 6
Key Therapeutic Areas 6
ACADIA Pharmaceuticals Inc. – Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products – Monotherapy 9
Pipeline Products – Combination Treatment Modalities 10
ACADIA Pharmaceuticals Inc. – Pipeline Products Glance 11
ACADIA Pharmaceuticals Inc. – Late Stage Pipeline 11
Registration Filed Products/Combination Treatment Modalities 11
Phase III Products/Combination Treatment Modalities 12
ACADIA Pharmaceuticals Inc. Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
ACADIA Pharmaceuticals Inc.–Early Stage Pipeline Products 15
Pre-Clinical Products/Combination Treatment Modalities 15
ACADIA Pharmaceuticals Inc. – Drug Profiles 16
AM-831 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Pimavanserin 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Pimavanserin + Risperidone 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
AC 262271 20
Product Description 20
Mechanism of Action 20
R&D Progress 20

3. AC-260584 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
ACP-105 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
ACP-106 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
AM-831 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
ACADIA Pharmaceuticals Inc. – Pipeline Analysis 25
ACADIA Pharmaceuticals Inc. – Pipeline Products by Therapeutic Class 25
ACADIA Pharmaceuticals Inc. - Pipeline Products By Target 26
ACADIA Pharmaceuticals Inc. – Pipeline Products by Route of Administration 27
ACADIA Pharmaceuticals Inc. – Pipeline Products by Molecule Type 28
ACADIA Pharmaceuticals Inc. – Recent Pipeline Updates 29
ACADIA Pharmaceuticals Inc. - Dormant Projects 30
ACADIA Pharmaceuticals Inc. – Company Statement 31
ACADIA Pharmaceuticals Inc. – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Financial Deals Landscape 34
ACADIA Pharmaceuticals Inc., Deals Volume Summary, 2004 to YTD 2011 34
ACADIA Pharmaceuticals Inc., Deals Summary By Region, 2004 to YTD 2011 35
ACADIA Pharmaceuticals Inc., Deals Summary, 2004 to YTD 2011 36
ACADIA Pharmaceuticals Inc. Detailed Deal Summary 37
Venture Financing 37
Abbey Pharmaceuticals Secures Seed Financing 37
Equity Offering 38
ACADIA Pharmaceuticals Completes Public Offering Of $102 Million 38
ACADIA Pharmaceuticals Completes Public Offering Of $63 Million 40
ACADIA Pharmaceuticals Completes Private Placement Of $36 Million 42
ACADIA Pharmaceuticals Completes Initial Public Offering Of $35 Million 45
ACADIA Pharmaceuticals Files Shelf Registration Statement For Public Offering Of
$29 Million 47
ACADIA Pharmaceuticals Expands Co-Development Agreement With Allergan 49
ACADIA Pharmaceuticals Enters Into Agreement With Meiji Seika Kaisha 50
ACADIA Pharmaceuticals Extends Co-Development Agreement With Allergan 51
ACADIA Pharmaceuticals Extends Co-Development Agreement With Allergan 52
ACADIA Pharmaceuticals Enters Into An Agreement With Sepracor 53
Licensing Agreements 55

4. Biovail Enters Into Licensing Agreement With ACADIA Pharmaceuticals 55
ACADIA Pharmaceuticals Enters Into Licensing Agreement With Ipsen 57
ACADIA Pharmaceuticals Enters Into Licensing Agreement with Abbey
Pharmaceuticals 58
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 60
Contact Us 60
Disclaimer 60
About Us:
ReportsnReports is an online library of over 100,000+ market research reports and
in-depth market research studies & analysis of over 5000 micro markets. We
provide 24/7 online and offline support to our customers. Get in touch with us for
your needs of market research reports.
Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page:
http://www.facebook.com/pages/ReportsnReports/191441427571689
Contact:
Mr.Priyank
7557 Rambler road,
Suite727,Dallas,TX75231
Tel: + 1 888 391 5441
E-mail: sales@reportsandreports.com
http://www.reportsnreports.com
Visit our Market Research Blog